Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Cash & Equivalents (2024 - 2025)

Allarity Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $14.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents changed N/A year-over-year to $14.7 million; the TTM value through Dec 2025 reached $14.7 million, changed N/A, while the annual FY2025 figure was $14.7 million, N/A changed from the prior year.
  • Cash & Equivalents reached $14.7 million in Q4 2025 per ALLR's latest filing, down from $18.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $19.2 million in Q2 2024 to a low of $312000.0 in Q1 2024.